BioPharma BoardRoom sat down with Simona Grandits, Senior Director, Head of Sales and Marketing EEMEA at QIAGEN, to delve into the company's recent strateg...
Biopharma M&A in 2023 Biopharma M&A activity has witnessed a decisive rebound in 2023, with aggregate deal value up by 79% vs. 2022 to reach ~$152...
From The BioPharma BoardRoom Lens The news of Tomas Blomquist stepping down from his role as CEO & President of Biotage AB carries sev...
The company is set to introduce multi-omics capabilities on the AVITI platform, along with enhancements to the first commercial Q50 kit and a host of workf...
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercial...
As we stand on the precipice of 2024, the life sciences industry continues its dynamic evolution, propelled by groundbreaking discoveries, technological ad...
The complexity of new biologics means that these life-changing therapeutics require complicated development and manufacturing processes. Product-specific c...
Medtronic plc announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8...
In an exclusive interview with BioPharma BoardRoom, Isabella Muñoz, Executive Director of Invest In Bogota, shares insights into how Bogota has posi...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its ...
Novo Nordisk announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg...
Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected financia...
Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales In...
Third-Quarter 2023 Revenues of $13.2 Billion Expected Decline in Paxlovid and Comirnaty(1) Revenues Drove 41% Operational Decrease in Third-Quarter 20...
© 2024 Biopharma Boardroom. All Rights Reserved.
